Skip to content

SRTA SRTA Restricted Cash

Restricted Cash at other companies

TransMedics Group, Inc. logo
TransMedics Group, Inc.TMDX
$18.44M+3,588%
GXO Logistics logo
GXO LogisticsGXO
$2M-97.8%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$923K
Kestra Medical Technologies, Ltd. Common Stock logo
Kestra Medical Technologies, Ltd. Common StockKMTS
$334K
RXO logo
RXORXO
$1M

Other financials

Income statement

See full
Revenue$67.4M+87.4%
Gross profit$14.1M+100%
Operating income-$3.0M+47.7%
Net income$2.2M+162%
EPS (diluted)$0.03+175%

Balance sheet

See full
Cash & equivalents$59.0M+65.3%
Total debt$4.5M-50.7%
Total equity$285.7M+30.0%
Total assets$327.6M+30.8%

Cash flow

See full
Operating cash flow$3.9M+1,679%
CapEx$5.2M+98.1%
Free cash flow-$1.3M+54.8%

Valuation

See full
Market cap$463.78M+24.0%
Enterprise value$409.26M
P/E8.9×
P/S1.8×

Profitability

See full
Gross margin21.7%+1.3pp
Operating margin-7.8%-2.8pp
Net margin21%+13.6pp
FCF margin-22.4%+1,712pp

Returns & leverage

See full
Return on equity15.6%+10.0pp
Debt / equity0.0×
Current ratio5.9×-1.0×

Where this comes from

Reported directly by SRTA in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalents.

The official record: SRTA’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about SRTA's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SRTA's restricted cash?
SRTA (SRTA) reported restricted cash of $264K in Q1 2026.
How has SRTA's restricted cash changed year-over-year?
SRTA's restricted cash decreased by 69.2% year-over-year, from $858K to $264K.
What is the long-term trend for SRTA's restricted cash?
Over 4 years (2021 to 2025), SRTA's restricted cash has grown at a -19.5% compound annual growth rate (CAGR), from $630K to $264K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.